## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.2% below STRENGTH zone (4.0-10.0%); PEG 1.94 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (54% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($253.60)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Is the Options Market Predicting a Spike in Labcorp Holdings Stock?**
- Source: TradingView â€” Track All Markets | 20251215T140849 | Somewhat-Bearish | Relevance: 100%
- The options market is showing a high implied volatility for Labcorp Holdings (LH) stock, particularly with the Feb 20, 2026 $135 Call. This suggests investors anticipate a significant price movement, possibly due to an upcoming event. Despite this, analysts currently rate Labcorp Holdings as a Zacks Rank #3 (Hold), with recent downward revisions to earnings estimates.

**2. Labcorp (LH): Reassessing Valuation After Reduced Growth Outlook for Contract Research Unit**
- Source: Simply Wall Street | 20251213T190811 | Neutral | Relevance: 100%
- Labcorp Holdings (LH) recently beat earnings expectations but has seen its stock react negatively due to management's cautious tone and reduced revenue growth targets for its contract research unit. Despite a long-term solid performance, the company faces reassessment by investors considering slower growth in a key unit. While analysts suggest it's undervalued with a fair value of $299.71, concerns about policy shifts and regulatory pressure could impact margins.

**3. Labcorp (LH): Reassessing Valuation After Reduced Growth Outlook for Contract Research Unit**
- Source: Simply Wall Street | 20251213T185008 | Somewhat-Bearish | Relevance: 100%
- Labcorp Holdings (LH) recently surpassed earnings expectations but saw its stock react negatively due to management's cautious outlook, including reduced revenue growth targets for its contract research unit and a trimmed full-year forecast. Despite a strong 5-year shareholder return, the stock's recent weakness suggests investors are reassessing growth risks. Analysts currently see Labcorp as undervalued with a fair value of $299.71, though its P/E ratio is higher than the broader US healthcare sector.

**4. What Labcorp Holdings (LH)'s Slowing Growth and Margin Pressure Means For Shareholders**
- Source: Simply Wall Street | 20251211T032445 | Somewhat-Bearish | Relevance: 100%
- Labcorp Holdings is facing challenges including persistently slow organic sales growth, declining adjusted operating margins, and a weaker return on invested capital. The company may need to reassess its cost structure and capital allocation strategies to address investor concerns about its profitability and growth opportunities. Despite these issues, Labcorp's ventures into precision oncology and digital pathology, including new ctDNA tests and AI collaborations, are seen as potential avenues for higher-value growth that could offset slower organic performance and aid margin recovery.

**5. What Labcorp Holdings (LH)'s Slowing Growth and Margin Pressure Means For Shareholders**
- Source: Simply Wall Street | 20251211T030826 | Somewhat-Bearish | Relevance: 100%
- Labcorp Holdings (LH) is facing concerns due to persistently slow organic sales growth, declining adjusted operating margins, and a weaker return on invested capital. The company's investment narrative highlights the need to stabilize profitability in its core businesses and the emergence of structural profitability issues as key risks. Despite these challenges, Labcorp's expanded precision oncology and digital pathology efforts offer potential offsets to slower organic growth and could aid in margin recovery.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Insider selling cluster: $3.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.94 elevated, pricing in significant growth expectations. Forward P/E 15.1x stretched relative to 7% growth. Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.0B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.94 |
| Forward P/E | 15.1 |
| Current P/E | 16.2 |
| YoY Growth | 7.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.7% to -0.2% (+3.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (2.3%) - potential reversal signal. RSI neutral at 50. Volume at 54% of 20MA suggests lack of conviction. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.23% (CS: 36) | Neutral |
| RSI_14 | 50.0 | Neutral |
| MACD Histogram | 0.16 | Bullish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 0.987x | Below |
| vs SMA200 | 1.026x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $264.18
- **Stop Loss:** $253.60 (4.0% risk)
- **Target:** $274.76 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 94
- **Position Value:** $24,832.92
- **Portfolio %:** 24.83%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*